Emkay Global Financial's research report on IndusInd Bank
IndusInd Bank (IIB) reported largely in-line PAT at Rs21.2bn (up 30% YoY)/RoA at 1.8%, led by healthy credit growth/NII and lower LLP, as the bank continued to utilize the contingent buffer of up to Rs2bn during 1Q; the buffer now stands at Rs17bn/0.6% of loans. Amid decelerating margins across banks (ex-HDFCB), IIB retained NIM at ~4.3% in 1Q. Going ahead, Bank targets accelerating its retailization strategy, which should keep margins/core-profitability healthy. Asset quality too is on the mend which, coupled with healthy PCR/contingent buffer, should lead to moderation in LLP and thus drive-up RoA/RoE to 1.8-1.9%/16-18% over FY24-26E. We believe that concerns around the MD’s shorter-tenure are largely behind, while stock performance will hereon track the improving growth (>20%), asset quality and RoA/RoE trajectory. Despite the recent run-up in the stock, IIB is trading at reasonable valuations — 1.6x its FY25E ABV.
Outlook
We value the stock at 2x Jun-25E ABV and revise the TP to Rs1,800/share (vs Rs1,600). We retain BUY on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
